home.aspx

 
. home.aspx home.aspx

ARCHIVED NEWS


    BIOGEN BETS $45M ON IONIS' PHASE 1 ALZHEIMER'S MED

    Dec 19, 2019

    Looks like Biogen is going all in on Alzheimer’s disease—the Big Biotech is picking up a tau-targeting treatment from Ionis Pharmaceuticals for $45 million upfront.  Currently in phase 1, the antisense treatment, IONIS-MAPTRx, is designed to cut down on the production of tau protein...

    FIERCEBIOTECH
    READ MORE

    /news-article.aspx?ID=37013701

    TURNSTONE TEAMS UP WITH TAKEDA IN $900M DEAL TO WORK ON BIOTECH'S ONCOLYTIC DRUG

    Dec 19, 2019

    Fierce 15 winner Turnstone Biologics has penned a near $1 billion biobucks deal with biotech’s best friend, Takeda. The pact, which has a substantial $120 million upfront in cash, sees Takeda gain an exclusive worldwide license to co-develop and co-commercialize Turnstone’s leading (but ...

    FIERCEBIOTECH
    READ MORE

    /news-article.aspx?ID=37023702

    RHEOS PENS ROCHE COLLAB FOR NEXT-GEN IMMUNOMETABOLISM RESEARCH

    Dec 19, 2019

    Rheos Medicines has sealed a near $800 million biobucks deal with Swiss major Roche to seek out and develop new meds for autoimmune and inflammatory diseases. Rheos’ work is focused on what it calls metabolism-tuning therapies and is targeting autoimmune disease and cancer via metabolic pathwa...

    FIERCEBIOTECH
    READ MORE

    /news-article.aspx?ID=37033703

    SCIENTISTS TAKE STEM CELLS AND CONVERT THEM TO HEART PACEMAKER CELLS

    Dec 17, 2019

    University of Houston associate professor of pharmacology Bradley McConnell is helping usher in a new age of cardiac pacemakers by using stem cells found in fat, converting them to heart cells, and reprogramming those to act as biologic pacemaker cells. He is reporting his work in the Journal of Mol...

    TECHNOLOGY NETWORKS
    READ MORE

    /news-article.aspx?ID=36983698

    NEW METHODS PROMISE TO SPEED UP DEVELOPMENT OF NEW PLANT VARIETIES

    Dec 17, 2019

    A University of Minnesota research team recently developed new methods that will make it significantly faster to produce gene-edited plants. They hope to alleviate a long-standing bottleneck in gene editing and, in the process, make it easier and faster to develop and test new crop varieties with tw...

    TECHNOLOGY NETWORKS
    READ MORE

    /news-article.aspx?ID=36993699

    TRANSCRIPTOMIC SWITCH TURNS HEALTHY LIVER TISSUE CANCEROUS

    Dec 17, 2019

    By combining RNA sequencing, bioinformatics and mathematical modeling, University of California San Diego School of Medicine and Moores Cancer Center researchers identified a sudden transcriptomic switch that turns healthy liver tissue cancerous. The finding was used to develop a quantitative analyt...

    TECHNOLOGY NETWORKS
    READ MORE

    /news-article.aspx?ID=37003700

    ITERUM THERAPEUTICS REELS FROM ANTIBIOTIC PHASE III FAIL

    Dec 12, 2019

    An antibiotic candidate developed by the Irish company Iterum Therapeutics has failed to meet the main goal of a phase III trial, a blow for efforts to meet the challenge of global antibiotic resistance. Iterum Therapeutics’ drug sulopenem was tested in a phase III trial that recruited 674 pat...

    LABIOTECH.EU
    READ MORE

    /news-article.aspx?ID=36953695

    THERAPEUTIC SOLUTIONS INTERNATIONAL ENTERS INTO MULTI-MILLION DOLLAR MASTER SALES AGREEMENT WITH TIVA BIO

    Dec 12, 2019

    Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announces today the signing of a Master Sales Agreement with Tiva Bio to distribute the nutraceutical line of products developed by TSOI. Products to be included in the Master Sales Agreement currently consists of NanoStilbene, NeuroSti...

    CISION PR NEWSWIRE
    READ MORE

    /news-article.aspx?ID=36973697

TRENDING NEWS


    STEM CELL MODELS OF HUMAN SPINE DEVELOPMENT UNVEILED

    Jan 15, 2020

    Scientists have created the first lab-dish models of the cellular clock, where each ‘tick’ stimulates the formation of the vertebra, which uses stem cells derived from adult human tissue. Over 20 years ago, Olivier Pourquié’s lab at Harvard University, US discovered a cellul...

    DRUG TARGET REVIEW
    READ MORE

    /news-article.aspx?ID=37233723

    BLUEBIRD BIO LAUNCHES FIRST GENE THERAPY FOR BETA THALASSEMIA IN GERMANY

    Jan 15, 2020

    The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio’s gene therapy, branded as Zynteglo, was given conditional market appr...

    LABIOTECH
    READ MORE

    /news-article.aspx?ID=37243724

    GENE THERAPY OFFERS HOPE FOR UNTREATABLE CTE BRAIN DISORDER

    Jan 14, 2020

    Researchers from Weill Cornell Medical College published a new study (“Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy”) in Human Gene Therapy that shows the feasibility of using gene therapy to treat the progressive neurodegenerative disorder chronic traumatic encepha...

    GENETIC LITERACY PROJECT
    READ MORE

    /news-article.aspx?ID=37253725

    EYEVENSYS’ GENE THERAPY FOR BLINDNESS BOOSTED WITH €27M SERIES B

    Jan 10, 2020

    The French company Eyevensys has raised €27M to fund the launch of a phase II trial for its lead candidate, a non-viral gene therapy for an eye condition called uveitis that can lead to blindness. The Series B round was led by the Boehringer Ingelheim Venture Fund. New investors to Eyevensys in...

    LABIOTECH.EU
    READ MORE

    /news-article.aspx?ID=37193719

    EMERGEX VACCINES SECURES €10M TO ADVANCE SYNTHETIC VACCINE DEVELOPMENT

    Jan 10, 2020

    The UK biotech Emergex Vaccines has raised over €9.9M in a Series A funding round, which will allow it to progress the development of vaccines against diseases such as dengue, influenza, and Ebola to phase I clinical trials. Emergex specializes in the development of ‘set-point’ vacc...

    LABIOTECH.EU
    READ MORE

    /news-article.aspx?ID=37203720

    FRENCH BIOTECH RAISES €19M TO HIT PHASE I WITH CANCER IMMUNOTHERAPY

    Jan 10, 2020

    Alderaan Biotechnology has raised an €18.5M Series A round to push its lead cancer immunotherapy drug to phase I.  The UK VC firm Medicxi and the returning French VC investor Advent France Biotechnology contributed to the round. Alderaan, whose name was inspired by a fictional planet in th...

    LABIOTECH.EU
    READ MORE

    /news-article.aspx?ID=37213721

    ADAPTIVE PHAGE GETS $10M FROM DOD FOR ANTIBACTERIAL PHAGE THERAPIES

    Jan 08, 2020

    A company developing treatments for drug-resistant bacterial infections is getting a boost from the Department of Defense. Gaithersburg, Maryland-based Adaptive Phage Therapeutics, also known as APT, said Tuesday that it the DoD had awarded it $10.2 million to fund a clinical trial to develop its pe...

    MEDCITY NEWS
    READ MORE

    /news-article.aspx?ID=37163716

    MELANOMA IMMUNOTHERAPY ENHANCED BY TARGETING TREG CELL CONTROL PROTEIN

    Jan 08, 2020

    Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a new potential strategy for boosting the immune system’s ability to fight cancer. Studies in gene knockout mice, carried out in collaboration with a team at NYU Langone’s Perlmutter Cancer Center, suggested...

    GENETIC ENGINEERING AND BIOTECHNOLOGY NEWS
    READ MORE

    /news-article.aspx?ID=37173717

    THERACHON FOUNDERS SPIN OUT NEW RARE DISEASE BIOTECH WITH €31M INVESTMENT

    Jan 08, 2020

    The founders of Swiss biotech Therachon have launched a new company called VectivBio, also based in Basel, with €31M funding to develop drugs for rare diseases. The spin-out comes after Therachon was acquired by Pfizer last year in a deal worth up to €700M. Therachon’s CEO, CBO, CFO ...

    LABIOTECH.EU
    READ MORE

    /news-article.aspx?ID=37183718

    €5M INVESTMENT TO FUND FRENCH BIOTECH’S RESISTANCE-BUSTING ANTIBIOTIC

    Jan 06, 2020

    Mutabilis has received a €5M investment from the Danish VC Novo Holdings’ REPAIR Impact Fund to fuel the development of a new class of antibiotics that could kill drug-resistant strains of gram-negative bacteria. The French company will use the money to advance one of its preclinical drug...

    LABIOTECH.EU
    READ MORE

    /news-article.aspx?ID=37133713

    KRAS CRAZE SEES MERCK PUT $2.5B BIOBUCKS DOWN FOR TAIHO, ASTEX LICENSING DEAL

    Jan 06, 2020

    KRAS and its hope against cancer was one of the biggest talking points in 2019, and it seems this hype is not dying down in 2020. This morning, Merck & Co. said it was willing to put as much as $2.5 billion on the table (though very heavily backloaded) to gain access to small-molecule inhibitors...

    FIERCEBIOTECH
    READ MORE

    /news-article.aspx?ID=37143714

    GENE THERAPY SHOWS PROMISE IN THE TREATMENT OF CHRONIC TRAUMATIC ENCEPHALOPATHY

    Jan 06, 2020

    Researchers from Weill Cornell Medical College led by Ronald G. Crystal, MD, the Bruce Webster professor of internal medicine and professor of genetic medicine and chairman, department of genetic medicine, published a new study (“Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopat...

    GENETIC ENGINEERING AND BIOTECHNOLOGY NEWS
    READ MORE

    /news-article.aspx?ID=37153715

SPOTLIGHT

A leading biotechnology company focused on serving individuals with rare diseases, will present research covering a broad range of rare bleeding disorders at the 26th Biennial International Society on Thrombosis and Haemostasis Congress (ISTH), July 8-13, 2017 in Berlin, Germany. Showcased in eight

RESOURCES

Events